Testing the Protective and Caring Effect of a Water-in-oil Formulation in Patients Suffering From Urinary and/or Fecal Incontinence and Requiring Incontinence Care Products

NCT ID: NCT06924502

Last Updated: 2025-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-06

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to test the protecting and caring effect of a protective balm on patients suffering from urinary and/or fecal incontinence and need incontinence care products.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients receive at least two applications of the test product in the application area daily for two weeks. An additional washing product is used during the entire application time. The caring and skin protecting effects, the skin tolerability and cosmetic efficacy of the test product will be assessed by a physician, a nurse and the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incontinence, Urinary Incontinence, Fecal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Blinding of sponsor label (blanco primary packaging)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Product (P-001230/2)

Patients receive at least two applications of the test product P-001230/2 in the application area every day. An additional washing product is used to clean the skin.

Group Type EXPERIMENTAL

Protective Balm

Intervention Type OTHER

The test product will be applied in addition to an additional washing product in the test area.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protective Balm

The test product will be applied in addition to an additional washing product in the test area.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is capable of understanding the information given to them and providing informed consent
* 70 years of age and older
* Patients with incontinence (fecal and/or urinary), requiring incontinence protection material
* Skin type on Fitzpatrick scale: Between I to IV

Exclusion Criteria

* Current cancer treatment such as chemotherapy, irradiation
* Documented allergies to skin care and / or skin cleansing products
* Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation
* Incontinence-associated dermatitis (IAD) stage \>1a
* Active skin disease at the test area
* Any topical medication at the test area within the last 3 days prior to the start of the study and / or hroughout te entire course of the study
* Mini-Mental-Status-Test (MMST) \< 20
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. August Wolff GmbH & Co. KG Arzneimittel

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinikum Dortmund

Dortmund, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clarissa Masur

Role: CONTACT

Vanessa Letmathe

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Prof. Dr. Thomas Reinbold

Role: primary

+49 231 953 19320

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GLS-02/2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Developing Of A New Incontinence Care Product
NCT02991833 COMPLETED EARLY_PHASE1